The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups
Abstract
Psychiatric disorders or drug addiction are often regarded as contraindications against the use of interferon alfa (IFN-α) in patients with chronic hepatitis C. Our aim was to obtain prospective data on adherence to as well as efficacy and mental side effects of treatment with IFN-α in different psychiatric risk groups compared with controls. In a prospective trial, 81 patients with chronic hepatitis C (positive hepatitis C virus[HCV] RNA and elevated alanine aminotransferase[ALT] level) and psychiatric disorders (n = 16), methadone substitution (n = 21), former drug addiction (n = 21), or controls without a psychiatric history or drug addiction (n = 23) were treated with a combination of IFN-α-2a 3 MU 3 times weekly and ribavirin (1,000-1,200 mg/d). Sustained virologic response (overall, 37%) did not differ significantly between subgroups. No significant differences between groups were detected with respect to IFN-α-related development of depressions during treatment. However, in the psychiatric group, significantly more patients received antidepressants before and during treatment with IFN-α (P < .001). Most of those who dropped out of the study were patients with former drug addiction (43%; P = .04) compared with 14% in the methadone group, 13% in the control group, and 18% in the psychiatric group. No patient in the psychiatric group had to discontinue treatment because of psychiatric deterioration. In conclusion, our data do not confirm the supposed increased risk for IFN-α-induced mental side effects and dropouts in psychiatric patients if interdisciplinary care and antidepressant treatment are available. Preexisting psychiatric disorders or present methadone substitution should no longer be regarded as contraindications to treatment of chronic hepatitis C with IFN-α and ribavirin in an interdisciplinary setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Lauer, G. M., & Walker, B. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450107 · Cited by 2,973
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · cited 4×
“049§ 2 7 (9) 3 (13) 0 2 (10) 2 (10) 3 30 (37) 4 (17) 4 (25) 13 (62)§ 9 (43)§ 4 3 (4) 1 (4) 1 (6) 0 1 (4) Cirrhosis (Child A) (%) 13 (16) 3 (13) 5 (31) 2 (10) 3 (14) NS Unknown* (%) 43 (53) 13 (43) 9 (56) 11 (52) 10 (48) Mode of infection (%) .”
InfluentialPoynard, T., Leroy, V, Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., & Zarski, J. P. (1996) · Hepatology · doi:10.1002/hep.510240405 · Cited by 671
Fattovich, G., Giustina, G., Favarato, S., & Ruol, A. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80184-x · Cited by 489
Psychiatric Complications of Long-term Interferon Alfa Therapy
Renault, P. F. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090055011 · Cited by 413
Mood and cognitive side effects of interferon-alpha therapy.
Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998) · PubMed · Cited by 312
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Side effects of therapy for chronic hepatitis C
Russo, M. W., & Fried, M. W. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00394-9 · Cited by 261
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
Self-citationMullish, B. H., Kabir, M. S., Thursz, M. R., & Dhar, A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12925 · Cited by 144
RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03316.x · Cited by 142
Depression and chronic liver diseases: are there shared underlying mechanisms?
Huang, X., Liu, X., & Yu, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00134 · Cited by 121
“IFN-α-associated depression develops in a total of 30–70% of HCV-infected patients during treatment, in which mild to moderate depression accounts for 45–60%, moderate to severe depression, 15–40%, and major depression, 15–45% (Raison et al., 2005a,b; Schaefer et al., 2002, 2003, 2007, 2012).”
BackgroundPsychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86
Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C
Amodio, P., De Toni, E. N., Cavalletto, L., Mapelli, D., Bernardinello, E., Del Piccolo, F., Bergamelli, C., Costanzo, R., Bergamaschi, F., Poma, S. Z., et al. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.09.004 · Cited by 61
Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy
HALLINAN, R., BYRNE, A., AMIN, J., & DORE, G. J. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03882.x · Cited by 56
Factors influencing adherence in Hepatitis-C infected patients: a systematic review
Mathes, T., Antoine, S.-L., & Pieper, D. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-203 · Cited by 44
Fahey, B., Hickey, B., Kelleher, D., O’Dwyer, A.-M., & O’Mara, S. M. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.05.005 · Cited by 43
WATSON, B., CONIGRAVE, K. M., WALLACE, C., WHITFIELD, J. B., WURST, F., & HABER, P. S. (2007) · Drug and Alcohol Review · doi:10.1080/09595230701247681 · Cited by 37
Hepatitis C Treatment for People With Severe Mental Illness
Mistler, L. A., Brunette, M. F., Marsh, B. J., Vidaver, R. M., Luckoor, R., & Rosenberg, S. D. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.2.93 · Cited by 39
Bonner, J. E., Barritt, A. S., Fried, M. W., & Evon, D. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2141-4 · Cited by 32
Fumaz, C. R., Muñoz-Moreno, J. A., Ballesteros, A. L., Paredes, R., Ferrer, M. J., Salas, A., Fuster, D., Masmitjà, E., Pérez-Álvarez, N., Gómez, G., et al. (2007) · AIDS Care · doi:10.1080/09540120600645539 · Cited by 30
Freedman, K., & Nathanson, J. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.1 · Cited by 16
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., Heldwein, W., Soyka, M., Grunze, H., Koenig, A., & Loeschke, K.
- Venue
- Hepatology
- Published
- 2003-02
- Volume
- 37
- Issue
- 2
- Pages
- 443-451
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2141559815
- Cited by
- 324
- References
- 32
- FWCI
- 22.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.